

---

**PRESS RELEASE**

---

**For Further Information Contact:**  
Patrick J. Muraca, President and CEO

**Nuclea Biotechnologies, LLC**  
105 South Street  
Pittsfield, MA 01201  
413-749-7405 (Ph)  
413-445-9930 (Fax)

**Nuclea Biotechnologies, LLC**  
Clark University  
Lasery Center for Bioscience  
Sackler Sciences Center  
950 Main Street  
Worcester, MA 01601  
Email: [pr@nucleabio.com](mailto:pr@nucleabio.com)  
[www.nucleabiotech.com](http://www.nucleabiotech.com)

---

**FOR IMMEDIATE RELEASE**

**NUCLEA BIOTECHNOLOGIES, LLC ANNOUNCES TODAY THE CLOSING OF A  
\$1 MILLION DOLLAR PRIVATE PLACEMENT**

**Worcester and Pittsfield, Massachusetts .....JULY 8<sup>th</sup>, 2009.....Nuclea Biotechnologies, LLC**  
Announced today the closing of a \$1 Million Dollar Private Placement. This offering is for Preferred Units of the Company. The Company had a Private Placement closing upon receiving commitments for \$1.0 million dollars of Preferred Units, prior to deducting placement agent fees, legal fees and other offering expenses payable by the Company.

The Nuclea's business strategy is as follows. Near-term, it is anticipated that growth will come from increasing sales of NDL's existing and new diagnostic assays, and increased service contracts between NBM and major pharmaceutical companies. In the mid-term, revenue growth should be enhanced by out-licensing and commercial collaborations with pharmaceutical companies of therapeutics developed by Nuclea's therapeutics subsidiary, NBT. In the long-term, Nuclea expects significant growth from the development and sale of pharmaceutical products arising out of the commercialization of Nuclea's patent protected intellectual property portfolio by NBT for its own account.

The proceeds will be used to finance the commercialization of the Company's diagnostic tests and the development of additional diagnostic tests, maintain and expand the Company's collaborations; and provide working capital for general business purposes.

"We are very pleased with this Private Placement closing of \$1 million dollars" states Patrick Muraca, President and CEO. "This infusion of new capital will allow the company to initiate the commercialization of its clinical laboratory business."

Nuclea Biotechnologies, LLC is a Delaware limited liability company based in Pittsfield and Worcester, Massachusetts. Nuclea has three lines of business, each of which is operated by a separate wholly-owned subsidiary: Nuclea Diagnostic Laboratories ("NDL") which has developed and is commercializing five unique diagnostic tests for colon, breast, leukemia, lung and prostate cancer; Nuclea Biomarkers ("NBM") which performs research leading to novel molecular oncology therapeutics and diagnostics for the pharmaceutical and biotechnology industries and performs services by analyzing and testing the efficacy and validating other indications of existing therapeutics utilizing a highly characterized and consented patient database; and Nuclea Biotherapeutics ("NBT") which has developed several therapeutics now in animal trials.

This press release contains forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. Such statements involve risks and uncertainties that could cause Nuclea's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in clinical trials, and drug development and commercialization.